- Home
- VOR vs TVRD Comparison
VOR vs TVRD Comparison
Compare VOR & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VOR
- TVRD
- Stock Information
- Founded
- VOR 2015
- TVRD 2017
- Country
- VOR United States
- TVRD United States
- Employees
- VOR N/A
- TVRD N/A
- Industry
- VOR Biotechnology: Pharmaceutical Preparations
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- VOR Health Care
- TVRD Health Care
- Exchange
- VOR Nasdaq
- TVRD Nasdaq
- Market Cap
- VOR 207.1M
- TVRD 246.5M
- IPO Year
- VOR 2021
- TVRD N/A
- Fundamental
- Price
- VOR $8.28
- TVRD $4.11
- Analyst Decision
- VOR Buy
- TVRD Buy
- Analyst Count
- VOR 7
- TVRD 7
- Target Price
- VOR $70.43
- TVRD $51.67
- AVG Volume (30 Days)
- VOR 1.0M
- TVRD 152.4K
- Earning Date
- VOR 11-13-2025
- TVRD 11-13-2025
- Dividend Yield
- VOR N/A
- TVRD N/A
- EPS Growth
- VOR N/A
- TVRD N/A
- EPS
- VOR N/A
- TVRD N/A
- Revenue
- VOR N/A
- TVRD N/A
- Revenue This Year
- VOR N/A
- TVRD N/A
- Revenue Next Year
- VOR N/A
- TVRD N/A
- P/E Ratio
- VOR N/A
- TVRD N/A
- Revenue Growth
- VOR N/A
- TVRD N/A
- 52 Week Low
- VOR $2.62
- TVRD $3.78
- 52 Week High
- VOR $65.80
- TVRD $43.65
- Technical
- Relative Strength Index (RSI)
- VOR 26.51
- TVRD 24.76
- Support Level
- VOR $7.60
- TVRD $3.85
- Resistance Level
- VOR $8.77
- TVRD $4.15
- Average True Range (ATR)
- VOR 0.98
- TVRD 0.28
- MACD
- VOR -0.01
- TVRD 0.85
- Stochastic Oscillator
- VOR 13.19
- TVRD 53.73
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.